JP2025518638A5 - - Google Patents

Info

Publication number
JP2025518638A5
JP2025518638A5 JP2025513495A JP2025513495A JP2025518638A5 JP 2025518638 A5 JP2025518638 A5 JP 2025518638A5 JP 2025513495 A JP2025513495 A JP 2025513495A JP 2025513495 A JP2025513495 A JP 2025513495A JP 2025518638 A5 JP2025518638 A5 JP 2025518638A5
Authority
JP
Japan
Prior art keywords
transposase
protein
vitro method
nucleic acid
aptamer
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2025513495A
Other languages
English (en)
Japanese (ja)
Other versions
JP2025518638A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/EP2023/062736 external-priority patent/WO2023218021A1/en
Publication of JP2025518638A publication Critical patent/JP2025518638A/ja
Publication of JP2025518638A5 publication Critical patent/JP2025518638A5/ja
Pending legal-status Critical Current

Links

JP2025513495A 2022-05-13 2023-05-12 導入遺伝子の発現および核局在化を改善するためのトランスポザーゼの使用 Pending JP2025518638A (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US202263341619P 2022-05-13 2022-05-13
US63/341,619 2022-05-13
EP22191966.5 2022-08-24
EP22191966 2022-08-24
PCT/EP2023/062736 WO2023218021A1 (en) 2022-05-13 2023-05-12 Use of transposases for improving transgene expression and nuclear localization

Publications (2)

Publication Number Publication Date
JP2025518638A JP2025518638A (ja) 2025-06-18
JP2025518638A5 true JP2025518638A5 (cg-RX-API-DMAC7.html) 2026-04-08

Family

ID=86605260

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2025513495A Pending JP2025518638A (ja) 2022-05-13 2023-05-12 導入遺伝子の発現および核局在化を改善するためのトランスポザーゼの使用

Country Status (7)

Country Link
EP (1) EP4522735A1 (cg-RX-API-DMAC7.html)
JP (1) JP2025518638A (cg-RX-API-DMAC7.html)
KR (1) KR20250010025A (cg-RX-API-DMAC7.html)
CN (1) CN119487184A (cg-RX-API-DMAC7.html)
AU (1) AU2023269540A1 (cg-RX-API-DMAC7.html)
CA (1) CA3253152A1 (cg-RX-API-DMAC7.html)
WO (1) WO2023218021A1 (cg-RX-API-DMAC7.html)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN118185901B (zh) * 2022-12-12 2025-03-21 北京精缮生物科技有限责任公司 一种PBase蛋白、融合蛋白、核酸和基因整合系统及应用
CN120400094A (zh) * 2025-04-28 2025-08-01 上海领康时代生物技术有限公司 一种重组PBase转座酶、PiggyBac载体系统及通过其构建的基因重组细胞

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2008027384A1 (en) * 2006-08-28 2008-03-06 University Of Hawaii Methods and compositions for transposon-mediated transgenesis
EP3714055A1 (en) * 2017-11-21 2020-09-30 CRISPR Therapeutics AG Materials and methods for treatment of autosomal dominant retinitis pigmentosa
EP3898967A1 (en) * 2018-12-17 2021-10-27 Consejo Superior de Investigaciones Científicas (CSIC) Method for the introduction of genetic information in cell by site-specific integration system
WO2020243085A1 (en) 2019-05-24 2020-12-03 The Trustees Of Columbia University In The City Of New York Engineered cas-transposon system for programmable and site-directed dna transpositions
WO2021216625A1 (en) * 2020-04-20 2021-10-28 Integrated Dna Technologies, Inc. Optimized protein fusions and linkers
JP2023529844A (ja) * 2020-06-05 2023-07-12 ザ・リージエンツ・オブ・ザ・ユニバーシテイー・オブ・カリフオルニア エピゲノム編集のための組成物及び方法
CA3173696A1 (en) * 2020-07-17 2022-01-20 Volker Sandig Hyperactive transposons and transposases
AU2021403660A1 (en) 2020-12-16 2023-07-06 Universitat Pompeu Fabra Programmable transposases and uses thereof

Similar Documents

Publication Publication Date Title
JP6946384B2 (ja) 脂質ナノ粒子を含む医薬組成物
JP6921797B2 (ja) ヒト疾患に関連する生物製剤およびタンパク質の産生のための修飾ポリヌクレオチド
KR102595683B1 (ko) 변형된 가이드 rna
CN109803977B (zh) 核酸产品及其施用方法
EP3443086B1 (en) Cas9 fusion molecules, gene editing systems, and methods of use thereof
JP5902679B2 (ja) IL−4Rαに結合する涙液リポカリンムテイン
TW202136509A (zh) 用於基因編輯之經修飾引導rna
US20200340012A1 (en) Crispr-cas genome engineering via a modular aav delivery system
JP2022507454A5 (cg-RX-API-DMAC7.html)
JP2022540318A5 (cg-RX-API-DMAC7.html)
JP2023554504A5 (cg-RX-API-DMAC7.html)
JP2022519507A5 (cg-RX-API-DMAC7.html)
JP2024531486A (ja) 環状rnaを調製するための構築物及び方法
JP2023534693A5 (cg-RX-API-DMAC7.html)
JP2022545950A5 (cg-RX-API-DMAC7.html)
TW202003053A (zh) 基因治療構築體及使用方法
JP2025515503A5 (cg-RX-API-DMAC7.html)
AU2022339843A1 (en) Rna-guided genome recombineering at kilobase scale
JP2026500040A (ja) 複合体及びその使用
CN117721096A (zh) 重组人透明质酸酶变体及其应用
JP2023507034A5 (cg-RX-API-DMAC7.html)
JP2024515113A (ja) 重篤な疾患を処置するためのb細胞ベースのタンパク質工場の操作
JP2023553701A5 (cg-RX-API-DMAC7.html)
JP2025516484A5 (cg-RX-API-DMAC7.html)
JPWO2023120658A5 (cg-RX-API-DMAC7.html)